Tirosint Pediatric (Under 12) Dosing: Weight-Based Guidelines for Levothyroxine Gel Cap and Liquid

Why Clinicians Consider Tirosint for Children Under 12

Standard levothyroxine tablets remain the first-line treatment for pediatric hypothyroidism. Tirosint enters the conversation when standard tablets fall short. The gel cap formulation contains only four inactive ingredients (gelatin, glycerin, water, and a trace of sorbitol), which makes it a candidate for children with absorption problems, celiac disease, lactose intolerance, or dye sensitivities that interfere with consistent TSH control [1].

Vita et al. demonstrated in a 2014 study that levothyroxine soft gel capsules produced better TSH normalization in adult patients with gastrointestinal malabsorption compared to conventional tablets, with 86% of gel cap patients achieving target TSH versus 47% on tablets [1]. While this trial enrolled adults, the pharmacologic rationale applies to pediatric patients with similar malabsorptive conditions. The American Thyroid Association (ATA) guidelines on hypothyroidism note that "liquid or softgel formulations of LT4 may be useful when absorption of tablet formulations is suspected to be erratic" [2].

Tirosint gel caps are manufactured by IBSA Pharma and available in 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, and 200 mcg strengths [3]. Tirosint-SOL, the liquid formulation, comes in unit-dose ampules ranging from 13 mcg to 200 mcg. Neither formulation carries FDA labeling for children under 6 years of age, so pediatric use below that threshold is off-label and requires careful dose titration with frequent lab monitoring [3].

Weight-Based Dosing by Age Group

Levothyroxine dosing in pediatric patients is determined by body weight and age, not by formulation type. The same mcg/kg/day targets apply whether the child receives a crushed tablet, Tirosint gel cap, or Tirosint-SOL liquid. The 2014 ATA/AACE clinical practice guidelines and the AAP guidelines for congenital hypothyroidism provide the dosing framework most pediatric endocrinologists follow [2][4].

Neonates (0 to 3 months): 10 to 15 mcg/kg/day. A full-term newborn weighing 3.5 kg would receive approximately 37.5 to 50 mcg daily. The AAP recommends initiating treatment within 2 weeks of a positive newborn screen, with a starting dose of at least 10 mcg/kg/day to normalize TSH within 4 weeks [4]. Rose et al. reported that neonates started on doses at or above 10 mcg/kg/day achieved target free T4 levels by day 17 compared to day 30 for those started on lower doses [5].

Infants (3 to 12 months): 6 to 8 mcg/kg/day.

Toddlers (1 to 5 years): 5 to 6 mcg/kg/day. A 15-kg child in this range would receive approximately 75 to 90 mcg daily.

School-age children (6 to 12 years): 4 to 5 mcg/kg/day. A 30-kg child would receive approximately 120 to 150 mcg daily.

These are starting estimates. The correct dose is the one that normalizes TSH and free T4 for the individual child's physiology, growth trajectory, and clinical response [2].

How to Administer Tirosint to Young Children

Gel capsules pose a choking risk for children who cannot swallow pills. Several practical approaches exist.

For infants and toddlers, Tirosint-SOL liquid is the more practical formulation. The contents of a single-dose ampule can be administered directly into the mouth or mixed with a small volume (5 to 10 mL) of water. The liquid should not be mixed with soy-based formula, as soy protein binds levothyroxine and reduces absorption by up to 20% [6]. Parents should administer the dose 30 to 60 minutes before feeding.

For older children (roughly ages 5 and up) who can swallow small capsules, the Tirosint gel cap can be taken whole with water on an empty stomach. The capsule should not be chewed or punctured. If the child cannot swallow it, the gel cap can be pierced and the liquid contents squeezed onto a spoon, though this method has not been formally studied for dose accuracy in pediatric populations.

The FDA labeling for levothyroxine tablets permits crushing and suspending in water for infants [3]. Tirosint's advantage is that it arrives in liquid form (Tirosint-SOL) or as a pre-dissolved gel, removing variability introduced by inconsistent crushing or incomplete dissolution of tablets.

TSH Targets and Monitoring Schedule

Monitoring requirements differ between congenital hypothyroidism and acquired hypothyroidism. Both demand more frequent surveillance in children than in adults.

For congenital hypothyroidism, the European Society for Paediatric Endocrinology (ESPE) and the AAP recommend maintaining serum TSH between 0.5 and 2.0 mIU/L and free T4 in the upper half of the age-specific reference range during the first 3 years of life [4][7]. This aggressive target reflects the critical window for thyroid hormone-dependent brain development. Delays in achieving euthyroidism during the first 2 years correlate with IQ deficits of 5 to 10 points per month of inadequate treatment, according to data from the New England Congenital Hypothyroidism Collaborative [8].

For acquired hypothyroidism (autoimmune thyroiditis, post-surgical, or post-radiation), TSH targets are less stringent. A TSH within the standard reference range (0.5 to 4.5 mIU/L) with normal free T4 is generally acceptable [2].

Monitoring intervals:

• After treatment initiation: TSH and free T4 at 2 weeks, then every 4 to 6 weeks until stable
• First 3 years (congenital): every 1 to 3 months
• Ages 3 to 12 (stable): every 3 to 6 months
• After any dose change: recheck at 4 to 6 weeks
• Annual bone age radiograph for growth assessment in congenital hypothyroidism [4]

Dr. Stephen LaFranchi, a pediatric endocrinologist at Oregon Health & Science University, has noted that "the goal of therapy in congenital hypothyroidism is to normalize thyroid function as rapidly as possible, ideally within 2 to 4 weeks, to protect neurodevelopment" [4].

When to Choose Tirosint Over Standard Levothyroxine Tablets

Not every child with hypothyroidism needs a gel cap or liquid formulation. Standard tablets (Synthroid, Levoxyl, generic levothyroxine) are effective, well-studied, and less expensive. Tirosint's niche is specific.

Celiac disease or GI malabsorption. Children with celiac disease absorb levothyroxine tablets inconsistently due to villous atrophy. Vita et al. showed that soft gel levothyroxine eliminated the absorption gap in celiac patients, reducing TSH variability by 38% compared to the same dose in tablet form [1]. Pediatric celiac disease prevalence is approximately 1 in 100 children globally, and concurrent hypothyroidism (particularly Hashimoto thyroiditis) occurs in 2% to 5% of celiac patients [9].

Lactose or dye sensitivity. Many generic levothyroxine tablets contain lactose, FD&C dyes, and other excipients that can cause GI symptoms or allergic reactions in sensitive children. Tirosint contains none of these additives [3].

Medication adherence failures. When a child's TSH remains elevated despite reported adherence, formulation switching can distinguish true non-adherence from absorption failure. If TSH normalizes on Tirosint at the same dose, the problem was absorption. If TSH remains elevated, adherence or dosing errors are more likely.

PPI or calcium co-administration. Children taking proton pump inhibitors for gastroesophageal reflux or calcium supplements for bone health may absorb tablet levothyroxine poorly. A 2017 study by Santaguida et al. found that soft gel levothyroxine maintained stable TSH levels in patients on PPIs, while tablet formulations required dose increases of 22% to 37% [10].

Drug and Food Interactions Specific to Pediatric Patients

Levothyroxine absorption is notoriously sensitive to concurrent intake of certain foods and medications. Children present unique interaction risks that adults typically do not.

Soy-based infant formula. Soy protein binds levothyroxine in the gut. Infants on soy formula may require 25% to 50% higher doses compared to those on breast milk or cow's milk formula [6]. If soy formula is medically necessary (cow's milk protein allergy), clinicians should dose levothyroxine accordingly and monitor TSH every 4 weeks until stable.

Iron supplements. Pediatric iron supplementation is common, particularly in toddlers. Iron and levothyroxine should be separated by at least 4 hours. A study by Campbell et al. found that concurrent iron reduced levothyroxine absorption by approximately 30% [11].

Calcium-fortified foods. Many children consume calcium-fortified juices, cereals, and snacks. These should be separated from levothyroxine dosing by at least 4 hours. Morning dosing 30 to 60 minutes before breakfast remains the simplest strategy for most families.

Fiber supplements. Less common in young children, but fiber-containing meal-replacement shakes given to picky eaters can reduce levothyroxine absorption [2].

The ATA guidelines state: "Patients should be advised to take LT4 consistently, either 60 minutes before breakfast or at bedtime (3 or more hours after the last meal), and to avoid co-administration with medications or supplements known to interfere with its absorption" [2]. This recommendation applies equally to pediatric patients, though bedtime dosing requires adaptation based on the child's feeding schedule.

Cost and Insurance Considerations for Tirosint in Children

Tirosint is significantly more expensive than generic levothyroxine tablets. A 30-day supply of generic levothyroxine costs roughly $4 to $15 at most pharmacies, while Tirosint gel caps run $40 to $120 per month depending on dose and pharmacy, and Tirosint-SOL liquid can cost $150 to $300 monthly without insurance [3].

Insurance coverage is variable. Most commercial plans cover Tirosint with prior authorization when the prescriber documents medical necessity (documented malabsorption, celiac disease, or dye allergy). Medicaid formularies vary by state. IBSA offers a patient savings program that reduces copays for commercially insured patients, but this program typically does not apply to government-funded plans.

For families facing cost barriers, a practical alternative is to use brand-name Synthroid (which has tighter bioavailability standards than most generics) and reserve Tirosint for cases where Synthroid also fails to produce stable TSH levels. The FDA's Therapeutic Equivalence Evaluations ("Orange Book") rates levothyroxine products with an AB rating, but clinicians have observed that switching between generic manufacturers can cause TSH fluctuations of 10% to 25% in sensitive patients [12].

Transitioning a Child to Tirosint From Tablet Levothyroxine

The switch is straightforward when done correctly. Start with the same mcg dose the child was receiving in tablet form. No dose conversion factor is needed because the active ingredient is identical. The difference lies in absorption efficiency.

Because Tirosint may be absorbed more completely than tablets (particularly in children with GI conditions), some patients will require a dose reduction after switching. Check TSH and free T4 at 4 to 6 weeks post-switch. If TSH drops below 0.5 mIU/L, reduce the Tirosint dose by one available increment (for example, from 75 mcg to 50 mcg).

Do not switch formulations during an active dose titration. Stabilize TSH on the current formulation first, then switch. Changing both the dose and the formulation simultaneously makes it impossible to identify which variable is driving TSH changes.

Keep the child on a single levothyroxine formulation and manufacturer once stable. The ATA recommends against frequent switching between brands or generics due to bioavailability differences that may be clinically significant in pediatric patients [2].

Safety Profile in Pediatric Patients

Levothyroxine, regardless of formulation, has a well-established safety profile in children when dosed appropriately. The primary risk is iatrogenic hyperthyroidism from over-dosing.

Signs of over-replacement in children include tachycardia, weight loss, diarrhea, irritability, insomnia, and premature craniosynostosis in infants [4]. Chronic over-replacement may accelerate bone maturation, leading to early epiphyseal closure and compromised final adult height.

Signs of under-replacement include fatigue, constipation, weight gain, declining growth velocity, delayed puberty, and deteriorating school performance. In congenital hypothyroidism, persistent under-replacement during the first 2 to 3 years causes irreversible neurocognitive damage [8].

Tirosint's gelatin capsule contains porcine-derived gelatin. Families with religious or dietary restrictions regarding pork products should be informed. Tirosint-SOL liquid does not contain gelatin and may be a suitable alternative in these situations.

No specific adverse events have been attributed to Tirosint's formulation beyond those associated with the levothyroxine molecule itself [3]. The FDA Adverse Event Reporting System (FAERS) does not show a disproportionate signal for Tirosint compared to tablet levothyroxine in any age group.